Article Text

Download PDFPDF
Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas
  1. M. Murakami*,
  2. H. Tsukada*,
  3. M. Shida*,
  4. M. Watanabe*,
  5. H. Maeda*,
  6. S. Koido*,
  7. T. Hirasawa*,
  8. T. Muramatsu*,
  9. T. Miyamoto*,
  10. S. Nasu,
  11. S. Yasuda,
  12. H. Kajiwara§,
  13. M. Yasuda§ and
  14. M. Ide
  1. *Department of Obstetrics & Gynecology, Tokai University School of Medicine, Isehara Kanagawa, Japan
  2. Department of Radiology, Tokai University School of Medicine, Isehara Kanagawa, Japan
  3. Department of Surgery, Tokai University School of Medicine, Isehara Kanagawa, Japan
  4. §Department of Pathology, Tokai University School of Medicine, Isehara Kanagawa, Japan
  5. Department of HIMEDIC Imaging Center, Lake Yamanaka, Yamanashi, Japan
  1. Address correspondence and reprint requests to: Masaru Murakami, MD, PhD, Department of Obstetrics and Gynecology, Tokai University Oiso Hospital, Tokai University School of Medicine, Oiso Town Kanagawa 259-0198, Japan. Email: masarumu{at}oiso.u-tokai.ac.jp

Abstract

We evaluated the usefulness of whole-body positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG-PET) for the detection of recurrence in follow-up patients after primary treatment of uterine sarcoma. Eight patients with pathologically proven uterine sarcoma underwent FDG-PET, computed tomography (CT), and ultrasonography (US). Final diagnoses of recurrence were established in five cases (three carcinosarcomas and two leiomyosarcomas). PET revealed recurrent sites in the intraperitoneum, liver, lung, bone, and retroperitoneal lymph nodes. However, the minimum size of the tumor detected by PET depended on the sites of recurrence. CT and US images showed two false-negative cases of intraperitoneal tumors. PET was able to detect a solitary small intraperitoneal tumor, which was very difficult to detect by CT and US. Positive PET findings did not affect the prognosis in three of the five recurrent patients; however, the remaining two patients consequently underwent the combination therapy consisting of surgery and chemotherapy and survived for more than 1 year after the positive FDG-PET results. Application of PET imaging for the early detection of recurrent sites was useful for the decision of treatment strategy for patients with recurrent uterine sarcoma.

  • FDG-PET
  • recurrent uterine sarcomas

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.